12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Idebenone: Phase III ongoing

Santhera said a DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III DELOS trial of 900 mg/day idebenone in up to 260 patients ages 10-18 years after the compound passed a planned interim futility and safety analysis. The DSMB told Santhera that the study has "a reasonable chance" of achieving its primary endpoint of improving or delaying the loss of...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >